Beata Stella‐Hołowiecka

Author

Also Known As

B Stella-Holowiecka, B Stella-Hołowiecka, B. Stella-Holowiecka, B. Stella-Hołowiecka, Beata M. Stella-Holowiecka, Beata Stella-Holowiecka, Beata Stella-Hołowiecka, Beata Stella‐Holowiecka, Beata Stella‐Hołowiecka

109

Publications

Citations

H-Index

Concepts

All Affiliations

Medical University of Silesia Jagiellonian University Medical University of Lodz Gdańsk Medical University Medical University of Warsaw

About

Beata Stella‐Hołowiecka is an author at Medical University of Silesia specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	486
2	Health Sciences	2	2	115
3	Cellular Therapies	2	2	82
4	Blood Transplantation	1	1	28
5	Cell Biology	1	1	60

Beata Stella‐Hołowiecka

Publications

849

Citations

H-Index

Page 1

	Year	Citations
Status of minimal residual disease after induction predicts outcome in both standard and high‐risk Ph‐negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4‐2002 MRD Study Jerzy Hołowiecki, Małgorzata Krawczyk‐Kuliś, Sebastian Giebel, British Journal of Haematology	2008	142
Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study Sebastian Grosicki, Tadeusz Robak, Sławomira Kyrcz‐Krzemień, Leukemia Hematological MalignancyMedicineAcute Myeloid LeukemiaHematologyPharmacology	2004	125
Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide As First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Polish Adult Leukemia Group (PALG-CLL3 Study) Tadeusz Robak, Krzysztof Jamroziak, Joanna Góra‐Tybor, Journal of Clinical Oncology Hematological MalignancyOncologyMixed-phenotype Acute LeukemiaMalignant Blood DisorderPharmacology	2010	99
A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in <i>FIP1L1‐PDGFRA‐</i>expressing patients Grzegorz Helbig, Beata Stella‐Hołowiecka, Mirosław Majewski, British Journal of Haematology	2008	81
Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial Tadeusz Robak, Krzysztof Jamroziak, Joanna Góra‐Tybor, Blood	2007	75
Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies Grzegorz Helbig, Beata Stella‐Hołowiecka, Jerzy Wojnar, Annals of Hematology Cell TherapyTransplantationMarrow TransplantationBone Marrow FailureDifferent Therapeutic Strategies	2007	60
Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL Sebastian Giebel, Beata Stella‐Hołowiecka, Małgorzata Krawczyk‐Kuliś, Bone Marrow Transplantation Adult AllBone Marrow FailureLaboratory HematologyHematologyPathology	2009	59
Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia Tadeusz Robak, Jerzy Z. Błoński, Marek Kasznicki, The Hematology Journal Hematological MalignancyOncologyChronic Lymphocytic LeukemiaMalignant Blood DisorderHematology	2002	43
Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia Tadeusz Robak, JZ Błoński, Marek Kasznicki, Leukemia Hematological MalignancyLymphoid NeoplasiaOncologyFront-line TherapyChronic Lymphocytic Leukemia	2001	34
Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia. Grzegorz Helbig, Beata Stella‐Hołowiecka, Małgorzata Krawczyk‐Kuliś, PubMed ImmunologyPathologyImmunotherapyAplastic AnemiaMyeloid Neoplasia	2005	28

Page 1